Patents Assigned to IMMURON LIMITED
-
Patent number: 10144775Abstract: The present invention relates to methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease (CD AD). In particular, the invention relates to antibodies that bind to C. difficile antigens and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile associated disease, shedding of C. difficile, and C. difficile associated mortality. The compositions of the present application comprise: mammalian or avian antibodies which bind to a C. difficile Toxin B; and mammalian or avian antibodies that bind to a C. difficile vegetative cell antigen and/or a C. difficile endospore antigen.Type: GrantFiled: April 17, 2014Date of Patent: December 4, 2018Assignee: IMMURON LIMITEDInventors: Dena Lyras, Melanie Hutton, Bliss Cunningham, Lucy Li, Glen Carter, Julian Rood
-
Patent number: 10117930Abstract: The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.Type: GrantFiled: April 27, 2010Date of Patent: November 6, 2018Assignee: Immuron LimitedInventors: Yaron Ilan, Gadi Lalazar, Tomer Adar, Meir Mizrahi, Ami Ben-Ya'acov
-
Patent number: 9943597Abstract: Methods and compositions for treating conditions including liver dysfunction, e.g., associated with fatty liver; glucose intolerance; and others, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations.Type: GrantFiled: August 17, 2011Date of Patent: April 17, 2018Assignee: Immuron LimitedInventors: Yaron Ilan, Gadi Lalazar, Tomer Adar, Meir Mizrahi, Ami Ben-Ya'acov
-
Patent number: 9402902Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: GrantFiled: December 23, 2013Date of Patent: August 2, 2016Assignee: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Publication number: 20160083457Abstract: The present invention relates to methods and compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease (CD AD). In particular, the invention relates to antibodies that bind to C. difficile antigens and are capable of inhibiting C. difficile infection, at least one symptom of C. difficile associated disease, shedding of C. difficile, and C. difficile associated mortality. The compositions of the present application comprise: mammalian or avian antibodies which bind to a C. difficile Toxin B; and mammalian or avian antibodies that bind to a C. difficile vegetative cell antigen and/or a C. difficile endospore antigen.Type: ApplicationFiled: April 17, 2014Publication date: March 24, 2016Applicant: IMMURON LIMITEDInventors: Dena LYRAS, Melanie HUTTON, Bliss CUNNINGHAM, Lucy LI, Glen CARTER, Julian ROOD
-
Publication number: 20140112938Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Patent number: 8637025Abstract: The present invention provides a method of treatment or prophylaxis of enteric disease caused by Gram negative bacteria. The method includes the step of administering a vaccine or a hyperimmune material raised against said vaccine to an individual. The vaccine comprises one or more cell wall antigens reactive in a manner characteristic of O group serotypes, or reactive in a manner characteristic of lipopolysaccharide associated antigens, and at least some of said antigens are separated from bacterial cell walls or wall fragments. The invention also provides composition containing hyperimmune material as well as uses of the composition and vaccine.Type: GrantFiled: March 4, 2004Date of Patent: January 28, 2014Assignee: Immuron LimitedInventors: Roy Michael Robins-Browne, Grant Thomas Rawlin, Gottfried Lichti
-
Publication number: 20130273074Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease.Type: ApplicationFiled: October 4, 2011Publication date: October 17, 2013Applicant: IMMURON LIMITEDInventors: Grant Thomas Rawlin, Zeil Rosenberg, Oren Fuerst
-
Publication number: 20130164302Abstract: The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner.Type: ApplicationFiled: December 14, 2012Publication date: June 27, 2013Applicant: Immuron LimitedInventor: Immuron Limited
-
Publication number: 20110200610Abstract: The present invention relates to immunomodulatory compositions comprising mammalian colostrum-derived immunoglobulin preparation and optionally further colostrums, milk or milk product component/s and any adjuvants for treating immune-related disorders. More specifically, the invention provides compositions comprising colostrum-derived anti-insulin immunoglobulin preparations for the treatment of Metabolic Syndrome. The invention further provides methods and uses of the immunomodulatory compositions for an active or passive immunization in a disease-antigen specific or non specific manner.Type: ApplicationFiled: September 10, 2010Publication date: August 18, 2011Applicant: Immuron LimitedInventors: Yaron ILAN, Gadi LALAZAR, Ami Ben YA'ACOV, Tomer ADAR
-
Publication number: 20100196495Abstract: The invention relates to a method, composition and inhaler system for treatment or prophylaxis of influenza infection in one or more subjects by applying to a surface selected from air filters, sick room surfaces and respiratory mucosal membranes at least one immune material selected from antibodies and fragments thereof which bind a least one Influenza A antigen selected from the group consisting of H1, H3 and H5, the immune material being derived from hyperimmune milk products such as hyperimmune colostrum said hyperimmune milk products being prepared by inoculation of mammals with antigen composed of a least one Influenza A antigen selected from H1, H3 and H5.Type: ApplicationFiled: October 9, 2009Publication date: August 5, 2010Applicant: IMMURON LIMITEDInventors: Grant Thomas RAWLIN, Gottfried LICHTI, Roy Michael ROBINS-BROWNE